... $16 Million Cash On Hand and No Debt ...NAPA Calif. Oct. 13 /- Senetek PLC (OTCBulle...Management and the Board of Directors are closely monitoring currente...CEO Frank Massino and CFO Bill O'Kelly have requested that a portion...

NAPA, Calif., Oct. 13 /PRNewswire-FirstCall/ -- Senetek PLC (OTC
Bulletin Board: SNKTY), a life sciences company engaged in the development
of technologies that target the science of healthy aging, announced today
that the company continues to maintain a strong, debt-free financial
position. Current cash balances are in excess of $16 Million; $10 Million
of which is invested in fully FDIC insured bank certificates of deposits
and $6 Million on deposit in a money market account with Columbia
Management, a wholly owned subsidiary of Bank of America, one of the
strongest and most stable financial institutions in the world.

Management and the Board of Directors are closely monitoring current
economic conditions relative to planned infrastructure spending and are
taking all necessary steps to manage cash reserves while developing new
technologies and investing in marketing and sales of current products to
ensure growth and profitability. Given the current economy, Senetek plans a
gradual build out of the infrastructure and new launches.

CEO, Frank Massino and CFO, Bill O'Kelly have requested that a portion
of their salaries be paid in stock in lieu of cash. This proposal will be
formally presented and voted upon at a board meeting this week. Existing
trading window rules have precluded company insiders from purchasing stock
since September 16, 2008. "By taking stock instead of cash salaries, the
executive team demonstrates its faith in the company while working to
conserve cash reserves," says Mr. O'Kelly.

The company will continue the launch of Pyratine-6(TM), Senetek's next
generation of skin care based on advanced cytokinin technology, which is
garnering support from leading dermatologists, plastic surgeons and thought
leaders in aesthetic medicine. Physician feedback has shown Pyratine-6(TM)
to be effective in treatments related to pre and post light facial peels,
post laser resurfacing and bruising from injectable fillers with clinical
trials being scheduled to confirm these findings. Senetek remains confident
that Pyratine-6(TM) revenues will reach a $10.8 Million annual run rate by
December 2009 as previously forecasted. By first establishing brand
credibility with key influencers, Senetek's growing sales team will have
the tools needed to quickly and effectively achieve sales goals.

"Despite current world economic uncertainty, Senetek is in a secure and
strong position to execute on its sales, marketing and development
strategy," says Mr. Massino. "Senetek's strength will continue to be the
development and commercialization of patentable products with treatment
advantages."

About Senetek, PLC

Senetek PLC (OTCBB: SNKTY) is a life sciences company engaged in the
development of technologies that target the science of healthy aging. The
company's extensive research collaborations have resulted in a strong
pipeline of patented compounds and products with broad therapeutic
applications and a leading presence in dermatology. Senetek collaborates
with established specialty pharmaceutical companies in the final
development and marketing of its proprietary products, most recently
resulting in the development of the best-selling anti-aging product sold in
the North American physician market. For more information, visit the
company's website at http://www.senetekplc.com.

This news release contains statements that may be considered 'forward-
looking statements' within the meaning of the Private Securities Litigation
Reform Act. Forward-looking statements by their nature involve substantial
uncertainty, and actual results may differ materially from those that might
be suggested by such statements. Important factors identified by the
Company that it believes could result in such material differences are
described in the Company's Annual Report on Form 10-K for the year 2007.
However, the Company necessarily can give no assurance that it has
identified or will identify all of the factors that may result in any
particular forward-looking statement materially differing from actual
results, and the Company assumes no obligation to correct or update any
forward-looking statements which may prove to be inaccurate, whether as a
result of new information, future events or otherwise.

(Date:10/9/2017)... , ... October 09, 2017 , ... At its national ... Christopher Stubbs, a professor in Harvard University’s Departments of Physics and Astronomy, has been ... a member of the winning team for the 2015 Breakthrough Prize in Fundamental physics ...

(Date:4/18/2017)... SUNNYVALE, Calif. , April 18, 2017 Socionext Inc., a ... prototype of a media edge server, the M820, which features the ... face recognition software provided by Tera Probe, Inc., will be showcased ... and at the NAB show at the Las Vegas ... ...

(Date:4/11/2017)... , April 11, 2017 No ... but researchers at the New York University Tandon ... of Engineering have found that partial similarities between ... systems used in mobile phones and other electronic ... The vulnerability lies in the fact ...